At present, CAR-T cells are not perfect. Since the CAR gene is transmitted to the genome of T cells by retrovirus or lentivirus, this delivery method causes the CAR gene to be randomly inserted into the genome of the recipient cell. Thereby causing potential genetic side effects. Researchers from the Memorial Sloan-Kettering Cancer Center (MSK) used the CRISPR-Cas9 technology to construct more efficient second-generation CAR-T cells.
The full name of CAR-T is Chimeric Antigen Receptor T-Cell Immunotherapy, chimeric antigen receptor T cell immunotherapy. New cell therapies with significant efficacy in the treatment of acute leukemia and non-Hodgkin's lymphoma are considered to be one of the most promising approaches to cancer treatment. Its basic principle is to use the patient's own immune cells to clear cancer cells. Since the Wei Zexi incident, the clinical application of autoimmune therapy has been "braked", and the confusion caused by poor supervision has finally been countered by this promising tumor treatment.
At present, CAR-T cells are not perfect. Since the CAR gene is transmitted to the genome of T cells by retrovirus or lentivirus, this delivery method causes the CAR gene to be randomly inserted into the genome of the recipient cell. Thereby causing potential genetic side effects.
Researchers from the Memorial Sloan-Kettering Cancer Center (MSK) used CRISPR-Cas9 technology to construct more potent CAR-T cells and enhanced tumor suppression in mice. This points to the potential of CRISPR-Cas9 technology in the treatment of CAR-T cells and contributes to the future development of cancer immunotherapy.
The research results were published in the latest issue (February 22) in Nature. The author of the article is Professor Michel Sadelain, who commemorates the Sloan-Kettering Cancer Center. He is committed to genetically modifying T cells and is immune to cancer. One of the pioneers of therapy. For this latest achievement, he said, "Cell cancer cells try to escape cancer treatment, so we need CAR-T cells that match cancer cells and seize them. This new finding points out that we can use gene editing technology. To enhance these 'potential treatments', we hope to continue exploring genome editing techniques and developing second-generation CAR-T cell therapies."
Qingdao Beautiful Skin Biotechnology Co., Ltd , https://www.hafilleresthetic.com